Open Access

Lentivirus‑mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti‑tumor effect of dendritic cell vaccination against pancreatic cancer in SCID‑hu mice

  • Authors:
    • Jin Wang
    • Mingbing Sun
    • Xinguo Zhu
    • Hua Zhao
    • Deli Mao
    • Zhe Zhang
    • Xin Zhao
  • View Affiliations

  • Published online on: May 31, 2019     https://doi.org/10.3892/ol.2019.10426
  • Pages: 1539-1547
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Programmed death receptor ligand 1 (PD‑L1), which belongs to the B7 family, is overexpressed in a variety of human cancer types and serves a crucial role in immune escape by malignant cells. Programmed death receptor 1 (PD‑1) is a specific PD‑L1 receptor. PD‑1/PD‑L1 signaling inhibits the antitumor effects of dendritic cell (DC) immunization for tumor treatment. The aim of the present study was to determine whether inhibiting PD‑L1 may increase the immunologic anti‑tumor effect of dendritic cells against pancreatic cancer. In the present study, PD‑L1 levels in non‑cancerous and malignant tissue samples were compared, and the impact of PD‑L1 downregulation on human pancreatic cancer PaTu8988 cells was determined by lentivirus‑based RNA interference and DC immunotherapy. PD‑L1 expression in pancreatic specimens was assessed by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry. PaTu8988 cells expressing reduced levels of PD‑L1 were generated by lentivirus‑based knockdown to assess the mechanism by which the inhibition of PD‑L1 signaling in DC immunization affects therapeutic outcomes in pancreatic cancer‑bearing SCID‑hu mice. PD‑L1 levels were markedly elevated in pancreatic adenocarcinoma samples compared with in non‑cancerous tissue. PD‑L1 silencing in pancreatic adenocarcinoma cells resulted in improved treatment outcomes of DC immunization in vitro and in vivo compared with traditional DC immunization. PD‑L1 silencing enhances the antitumor response of cytotoxic T cells by increasing interferon γ production in vitro. In vivo, this method prevented tumor growth and lung metastasis, and prolonged survival in the SCID‑hu model. In conclusion, the results of the present study suggested that suppressing PD‑L1 in malignant cells during DC immunization may be a useful tool for immunotherapy in pancreatic adenocarcinoma.
View Figures
View References

Related Articles

Journal Cover

August-2019
Volume 18 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang J, Sun M, Zhu X, Zhao H, Mao D, Zhang Z and Zhao X: Lentivirus‑mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti‑tumor effect of dendritic cell vaccination against pancreatic cancer in SCID‑hu mice. Oncol Lett 18: 1539-1547, 2019
APA
Wang, J., Sun, M., Zhu, X., Zhao, H., Mao, D., Zhang, Z., & Zhao, X. (2019). Lentivirus‑mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti‑tumor effect of dendritic cell vaccination against pancreatic cancer in SCID‑hu mice. Oncology Letters, 18, 1539-1547. https://doi.org/10.3892/ol.2019.10426
MLA
Wang, J., Sun, M., Zhu, X., Zhao, H., Mao, D., Zhang, Z., Zhao, X."Lentivirus‑mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti‑tumor effect of dendritic cell vaccination against pancreatic cancer in SCID‑hu mice". Oncology Letters 18.2 (2019): 1539-1547.
Chicago
Wang, J., Sun, M., Zhu, X., Zhao, H., Mao, D., Zhang, Z., Zhao, X."Lentivirus‑mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti‑tumor effect of dendritic cell vaccination against pancreatic cancer in SCID‑hu mice". Oncology Letters 18, no. 2 (2019): 1539-1547. https://doi.org/10.3892/ol.2019.10426